Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
Key PointsThis disposition involved 3,500 shares at $38.42 per share, totaling $134,470...
Nasdaq News: Markets
More News
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It
Key PointsKaren Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5...
Nasdaq News: Markets
Director At AtriCure Sells $134K Of Stock
It was reported on August 7, that Maggie Yuen, Director at AtriCure (NASDAQ:ATRC) executed a significant insider sell, according to an SEC filing. What Happened: According to a Form 4 filing with the U.S. Securities andread more...
Benzinga
Are Options Traders Betting on a Big Move in AtriCure Stock?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
Zacks
AtriCure to Participate at Upcoming Investor Conferences
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two upcoming investor conferences. AtriCures...
Business Wire
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript
AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by Benzingaread more...
Benzinga
AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of +500.00% and +1.39%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
AtriCure Reports Second Quarter 2026 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. Our team delivered healthy growth and a...
Business Wire
AtriCure to Announce Second Quarter 2026 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2026 financial results on Thursday, July 23...
Business Wire

Advertisement|Remove ads.